Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 17;13(2):193.
doi: 10.3390/antibiotics13020193.

Synthesis of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives as Promising Scaffolds for the Development of Antimicrobial Candidates Targeting Multidrug-Resistant Bacterial and Fungal Pathogens

Affiliations

Synthesis of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives as Promising Scaffolds for the Development of Antimicrobial Candidates Targeting Multidrug-Resistant Bacterial and Fungal Pathogens

Povilas Kavaliauskas et al. Antibiotics (Basel). .

Abstract

Infections caused by multidrug-resistant bacterial and fungal pathogens represent a significant global health concern, contributing to increased morbidity and mortality rates. Therefore, it is crucial to develop novel compounds targeting drug-resistant microbial strains. Herein, we report the synthesis of amino acid derivatives bearing an incorporated 4-hydroxyphenyl moiety with various substitutions. The resultant novel 3-((4-hydroxyphenyl)amino)propanoic acid derivatives 2-37 exhibited structure-dependent antimicrobial activity against both ESKAPE group bacteria and drug-resistant Candida species. Furthermore, these derivatives demonstrated substantial activity against Candida auris, with minimum inhibitory concentrations ranging from 0.5 to 64 µg/mL. Hydrazones 14-16, containing heterocyclic substituents, showed the most potent and broad-spectrum antimicrobial activity. This activity extended to methicillin-resistant Staphylococcus aureus (MRSA) with MIC values ranging from 1 to 8 µg/mL, vancomycin-resistant Enterococcus faecalis (0.5-2 µg/mL), Gram-negative pathogens (MIC 8-64 µg/mL), and drug-resistant Candida species (MIC 8-64 µg/mL), including Candida auris. Collectively, these findings underscore the potential utility of the novel 3-((4-hydroxyphenyl)amino)propanoic acid scaffold for further development as a foundational platform for novel antimicrobial agents targeting emerging and drug-resistant bacterial and fungal pathogens.

Keywords: 4-hydroxyphenyl moiety; ESKAPE group pathogens; amino acid derivatives.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Scheme 1
Scheme 1
Synthesis of hydrazides 3 and 6.
Scheme 2
Scheme 2
Synthesis of compounds 718.
Scheme 3
Scheme 3
Synthesis of compounds 1937.
Figure 1
Figure 1
The boiled egg model illustrates the ADME properties of selected antibacterial derivatives of 3-((4-hydroxyphenyl)amino)propanoic acid. Blue dots indicate compounds predicted to be P-gp substrates, potentially undergoing active efflux from the central nervous system (CNS). Conversely, red dots indicate compounds predicted not to be P-gp substrates and not expected to undergo active efflux from the CNS.
Figure 2
Figure 2
The boiled egg model illustrates the ADME properties of selected antifungal derivatives of 3-((4-hydroxyphenyl)amino)propanoic acid. Blue dots indicate compounds predicted to be P--gp substrates, potentially undergoing active efflux from the central nervous system (CNS). Conversely, red dots indicate compounds predicted not to be P-gp substrates and not expected to undergo active efflux from the CNS.

References

    1. Septimus E.J. Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach. Med. Clin. N. Am. 2018;102:819–829. doi: 10.1016/j.mcna.2018.04.005. - DOI - PubMed
    1. Rice L.B. Antimicrobial Stewardship and Antimicrobial Resistance. Med. Clin. N. Am. 2018;102:805–818. doi: 10.1016/j.mcna.2018.04.004. - DOI - PubMed
    1. De Oliveira D.M.P., Forde B.M., Kidd T.J., Harris P.N.A., Schembri M.A., Beatson S.A., Paterson D.L., Walker M.J. Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev. 2020;33:e00181-19. doi: 10.1128/CMR.00181-19. - DOI - PMC - PubMed
    1. Mulani M.S., Kamble E.E., Kumkar S.N., Tawre M.S., Pardesi K.R. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front. Microbiol. 2019;10:539. doi: 10.3389/fmicb.2019.00539. - DOI - PMC - PubMed
    1. Roch M., Sierra R., Andrey D.O. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. Clin. Microbiol. Infect. 2023;29:320–325. doi: 10.1016/j.cmi.2022.10.018. - DOI - PubMed

LinkOut - more resources